1.      Aihara T, Kumamaru H, Ishitobi M, Miyashita M, Miyata H, Tamura K, Yoshida M, Ogo E, Nagahashi M, Asaga S, Kojima Y, Kadoya T, Aogi K, Niikura N, Iijima K, Hayashi N, Kubo M, Yamamoto Y, Takeuchi Y, Imoto S, Jinno H: Prognosis and effectiveness of chemotherapy for medullary breast carcinoma. Breast Cancer Res Treat 196: 635-645, 2022.(IF3.831)

2.     Aokage K, Suzuki K, Saji H, Wakabayashi M, Kataoka T, Sekino Y, Fukuda H, Endo M, Hattori A, Mimae T, Miyoshi T, Isaka M, Yoshioka H, Nakajima R, Nakagawa K, Okami J, Ito H, Kuroda H, Tsuboi M, Okumura N, Takahama M, Ohde Y, Aoki T, Tsutani Y, Okada M, Watanabe SI; Japan Clinical Oncology Group. Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial. Lancet Respir Med. 2023 Mar 6:S2213-2600(23)00041-3. doi: 10.1016/S2213-2600(23)00041-3. Online ahead of print.

3.     Chin K, Yamamoto S, Takahashi M, Kadowaki S, Kubota Y, Amanuma Y, Okada M, Kanda M, Kimura Y, Nogi Y, Arimitsu Y, Kitagawa Y. Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3. Esophagus. 2022 Dec 23. doi: 10.1007/s10388-022-00972-z. Epub 2022 Dec 23.

4.     Emi M, Hmai Y, Yoshikawa T, Hirohata R, Osawa M, Okada M, Murakami Y, Nishibuchi I. Clinical Outcomes of Esophagectomy and Chemoradiotherapy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma. Anticancer Res. 2022 May;42(5):2791-2795.

5.     Fujiwara M, Mimae T, Tsutani Y, Miyata Y, Okada M. Complications and Survival After Lung Cancer Resection in Interstitial Lung Disease. Ann Thorac Surg. 2023 Mar;115(3):701-708. doi: 10.1016/j.athoracsur.2022.05.069. Epub 2022 Jul 19.

6.     Fujiwara Y, Takahashi Y, Okada M, Kishimoto T, Kondo S, Fujikawa K, Hayama M, Sugeno M, Ueda S, Komuro K, Lanasa M, Nakano T.　Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma. Oncologist. 2022 Sep 2;27(9):e703-e722. 

7.     Goda N, Sasada S, Shigematsu H, Masumoto N, Arihiro K, Nishikawa H, Sakaguchi S, Okada M, Kadoya T. The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer. Discov Oncol. 2022 Apr 19;13(1):27.

8.     Hagiyama M, Mimae T, Wada A, Takeuchi F, Yoneshige A, Inoue T, Kotoku N, Hamada H, Sekido Y, Okada M, Ito A. Possible Therapeutic Utility of anti-Cell Adhesion Molecule 1 Antibodies for Malignant Pleural Mesothelioma. Front Cell Dev Biol. 2022 Jul 12;10:945007. doi: 10.3389/fcell.2022.945007. eCollection 2022.

9.     Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, Ohsawa M, Hirohata R, Kitasaki N, Okada M. Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery. Anticancer Res. 2022 Dec;42(12):6037-6045.

10.  Hamai Y, Emi M, Ibuki Y, Murakami Y, Nishibuchi I, Nagata Y, Kurokawa T, Yoshikawa T, Hirohata R, Ohsawa M, Kitasaki N, Okada M. Prognostic value of quantitative parameters for esophageal squamous cell carcinoma determined by preoperative FDG-PET after trimodal therapy. Surgery. 2022 Aug;172(2):584-592. 

11.   Han J, Hayashi S, Takahashi RU, Hirohata R, Kurokawa T, Tashiro M, Yamamoto Y, Okada M, Tahara H. Leukocyte Telomeric G-Tail Length Shortening Is Associated with Esophageal Cancer Recurrence. J Clin Med. 2022 Dec 12;11(24):7385.

12.  Handa Y, Tsutani Y, Mimae T, Miyata Y, Ito H, Shimada Y, Nakayama H, Ikeda N, Okada M. Complex Segmentectomy for Hypermetabolic Clinical Stage IA Non-Small Cell Lung Cancer. Ann Thorac Surg. 2022 Apr;113(4):1317-1324.

13.  Handa Y, Tsutani Y, Mimae T, Miyata Y, Shimada Y, Ito H, Nakayama H, Ikeda N, Okada M. A Multicenter Study of Complex Segmentectomy Versus Wedge Resection in Clinical Stage 0-IA Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 Jul;23(5):393-401. 

14.  Hasegawa S, Yokoi K, Okada M, Tanaka F, Shimokawa M, Daimon T, Nakano T. Neoadjuvant pemetrexed plus cisplatin followed by pleurectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2022 Jun;163(6):1940-1947.

15.  Hashimoto M, Yamamoto H, Endo S, Okada M, Miyata H, Hasegawa S, Chida M. Japanese Current Status of Curative-Intent Surgery for Malignant Pleural Mesothelioma. Ann Thorac Surg. 2022 Apr;113(4):1348-1353.

16.  Hata A, Shiraishi Y, Inui N, Okada M, Morise M, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T. Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE). Oncol Ther. 2022 Jun;10(1):253-262.

17.  Hiraoka E, Masumoto N, Furukawa T, Kuraoka N, Nagamine I, Kido A, Sentani K, Ootagaki S. Follicular lymphoma without lymphadenopathy incidentally diagnosed by sentinel lymph node biopsy during breast cancer surgery: a case report. Surg Case Rep. 2022 Sep 13;8(1):167. doi: 10.1186/s40792-022-01524-4.

18.  Hirohata R, Hamai Y, Hihara J, Emi M, Kurokawa T, Yoshikawa T, Ohsawa M, Kitasaki N, Okada M. Evaluation of Neoadjuvant Chemoradiotherapy Followed by Surgery for Borderline Resectable Esophageal Squamous Cell Carcinoma. World J Surg. 2022 Aug;46(8):1934-1943. 

19.  Ikejiri H, Sasada S, Emi A, Masumoto N, Kadoya T, Okada M. Dual-phase FDG PET/CT for predicting prognosis in operable breast cancer. Breast. 2022 Oct;65:98-103. 

20. Ito M, Miyata Y, Hirano S, Irisuna F, Kushitani K, Kai Y, Kishi N, Tsutani Y, Takeshima Y, Okada M. Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma. J Cancer Res Clin Oncol. 2022 Jun;148(6):1419-1428. 

21.  Ito M, Miyata Y, Kushitani K, Ueda D, Takeshima Y, Okada M. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma. BMC Cancer. 2023 Mar 14;23(1):248. doi: 10.1186/s12885-023-10716-6.

22. Ito M, Miyata Y, Okada M. Current clinical trials with non-coding RNA-based therapeutics in malignant diseases: A systematic review. Transl Oncol. 2023 Feb 23;31:101634. doi: 10.1016/j.tranon.2023.101634. Epub 2023 Feb 23.

23. Kagimoto A, Tsutani Y, Kushitani K, Kambara T, Mimae T, Miyata Y, Takeshima Y, Okada M. Usefulness of serum S100A4 and positron-emission tomography on lung cancer accompanied by interstitial pneumonia. Thorac Cancer. 2023 Feb;14(4):381-388. doi: 10.1111/1759-7714.14757. Epub 2022 Dec 19.

24. Kagimoto A, Tsutani Y, Mimae T, Miyata Y, Okada M. Segmentectomy versus wedge resection for radiological solid predominant and low metabolic non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2022 May 2;34(5):814-821.

25. Kagimoto A, Tsutani Y, Okada M. Segmentectomy for Spread Through Air Spaces-positive Lung Adenocarcinoma. Ann Thorac Surg. 2022 Nov;114(5):1989-1990. 

26. Kagimoto A, Tsutani Y, Shimada Y, Mimae T, Miyata Y, Ito H, Nakayama H, Ikeda N, Okada M. Oncological outcome of segmentectomy for early-stage non-small-cell lung cancer with invasive characteristics: a multicentre study. Eur J Cardiothorac Surg. 2022 Jul 11;62(2):ezac055. doi: 10.1093/ejcts/ezac055.

27. Kagimoto A, Tsutani Y, Shimada Y, Mimae T, Miyata Y, Ito H, Nakayama H, Ikeda N, Okada M. Segmentectomy for clinically early-stage primary squamous cell carcinoma of the lung. Thorac Cancer.  2022 Dec;13(24):3477-3485.

28. Kamigaichi A, Aokage K, Ikeno T, Wakabayashi M, Miyoshi T, Tane K, Samejima J, Tsuboi M. Long-term survival outcomes after lobe-specific nodal dissection in patients with early non-small-cell lung cancer. Eur J Cardiothorac Surg. 2023;63:ezad016.

29. Kamigaichi A, Aokage K, Katsumata S, Ishii G, Wakabayashi M, Miyoshi T, Tane K, Samejima J, Tsuboi M. Prognostic impact of examined mediastinal lymph node count in clinical N0 non-small cell lung cancer. Eur J Cardiothorac Surg. 2022;62:ezac359.

30. Kamigaichi A, Mimae T, Amioka J, Aoki G, Yoshimura K, Kawamoto N, Tsubokawa N, Miyata Y, Okada M. Segmentectomy preserves better immune-nutritional status than lobectomy in patients with early-stage lung cancer. Eur J Cardiothorac Surg. 2023 Feb 3;63(2):ezad019. doi: 10.1093/ejcts/ezad019.

31.  Kamigaichi A, Mimae T, Tsubokawa N, Miyata Y, Adachi H, Shimada Y, Ito H, Ikeda N, Okada M. Risk factors for recurrence of stage I epidermal growth factor receptor mutated lung adenocarcinoma. Ann Thorac Surg. 2023 Feb 2:S0003-4975(23)00089-9. doi: 10.1016/j.athoracsur.2023.01.024. Online ahead of print.

32. Kamigaichi A, Mimae T, Tsubokawa N, Miyata Y, Adachi H, Shimada Y, Ito H, Ikeda N, Okada M. Wedge resection is an acceptable treatment option for radiologically low-grade lung cancer with solid predominance. Interdiscip Cardiovasc Thorac Surg. 2023 Jan 9;36(1):ivac285. doi: 10.1093/icvts/ivac285.

33. Kamigaichi A, Tsutani Y, Handa Y, Mimae T, Miyata Y, Okada M. Feasibility of repeated ipsilateral anatomical pulmonary resection. Surg Today. 2023 Mar;53(3):379-385. doi: 10.1007/s00595-022-02604-6. Epub 2022 Oct 19.

34. Kamigaichi A, Tsutani Y, Mimae T, Miyata Y, Adachi H, Shimada Y, Takeshima Y, Ito H, Ikeda N, Okada M. Discrepancy Between Radiological and Pathological Tumor Size in Early-Stage Non-Small Cell Lung Cancer: A Multicenter Study. Semin Thorac Cardiovasc Surg. 2022 Dec 10:S1043-0679(22)00277-5. doi: 10.1053/j.semtcvs.2022.12.001. Online ahead of print.

35. Kamigaichi A, Tsutani Y, Mimae T, Miyata Y, Shimada Y, Ito H, Nakayama H, Ikeda N, Okada M. The prognostic impact of the ground-glass opacity component in nearly pure-solid stage IA non-small-cell lung cancer. Eur J Cardiothorac Surg. 2022 Aug 3;62(3):ezac166.

36. Kanou A, Masumoto N, Fukui K, Yokozaki M, Sasada S, Emi A, Kadoya T, Arihiro K, Okada M. The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively. J Med Ultrason (2001). 2022 Oct;49(4):709-717. 

37. Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50). Esophagus. 2022 Nov 19. doi: 10.1007/s10388-022-00970-1. Epub 2022 Nov 19.

38. Kawamoto N, Tsutani Y, Kamigaichi A, Ohsawa M, Mimae T, Miyata Y, Okada M. Tumour Location Predicts Occult N1 Nodal Metastasis in Clinical Stage I Non-small Cell Lung Cancer. Eur J Cardiothorac Surg. 2023 Feb 3;63(2):ezac575. doi: 10.1093/ejcts/ezac575.

39. Kawamoto N, Tsutani Y, Okada M. Reply to Sanz-Santos et al. Eur J Cardiothorac Surg 63: ezad084, 2023.

40. Kenmotsu H, Sugawara S, Watanabe Y, Saito H, Okada M, Chen-Yoshikawa TF, Ohe Y, Nishio W, Nakagawa S, Nagao H.　Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010).　Cancer Sci. 2022 Dec;113(12):4327-4338. 

41.  Kimura Y, Masumoto N, Kanou A, Fukui K, Sasada S, Emi A, Kadoya T, Arihiro K, Okada M. The TILs-US score on ultrasonography can predict the pathological response to neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive and triple-negative breast cancer. Surg Oncol. 2022 May;41:101725. doi: 10.1016/j.suronc.2022.101725. Epub 2022 Feb 15.

42. Kimura Y, Sasada S, Emi A, Masumoto N, Kadoya T, Arihiro K, Okada M. 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Tumor Immune Microenvironment Function in Early Triple-negative Breast Cancer. Anticancer Res. 2023 Jan;43(1):127-136. doi: 10.21873/anticanres.16141.

43. Kitasaki N, Hamai Y, Emi M, Kurokawa T, Yoshikawa T, Hirohata R, Ohsawa M, Okada M. Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery. In Vivo. 2022 Nov-Dec;36(6):2852-2860.

44. Mimae T, Miyata Y, Kumada T, Handa Y, Tsutani Y, Okada M. Interstitial pneumonia and advanced age negatively influence postoperative pulmonary function. Interact Cardiovasc Thorac Surg. 2022 May 2;34(5):753-759. 

45. Mimae T, Miyata Y, Kumada T, Tsutani Y, Okada M. The intersegmental pulmonary vein is not always located on the intersegmental plane of the lung: Evaluation with 3-dimensional volume-rendering image reconstruction. JTCVS Tech. 2022 Sep 13;16:132-138.

46. Mimae T, Miyata Y, Tsutani Y, Shimada Y, Ito H, Nakayama H, Ikeda N, Okada M.　Role of ground-glass opacity in pure invasive and lepidic component in pure solid lung adenocarcinoma for predicting aggressiveness.　JTCVS Open. 2022 May 2;11:300-316. doi: 10.1016/j.xjon.2022.04.041. eCollection 2022 Sep.

47. Mimae T, Okada M. Commentary: Segmentectomy as a standard surgery, a new era in small sized, peripheral, non-small cell lung cancer. JTCVS Tech. 2022 Feb 20;12:210-211. doi: 10.1016/j.xjtc.2022.02.013. eCollection 2022 Apr.

48. Mimae T, Satouchi M, Okada M.　Psychological states regarding adjuvant chemotherapy in patients with non-small cell lung cancer.　Cancer Treat Res Commun. 2022 Jul;23(5):393-401. doi: 10.1016/j.cllc.2021.10.005. Epub 2022 Apr 27.

49. Miyazaki T, Saji H, Nakamura H, Nagayasu T, Okumura N, Tsuchida M, Sonobe M, Aokage K, Nakao M, Haruki T, Okada M, Suzuki K, Chida M, Yoshino I; Committee for Scientific Affairs, The Japanese Association for Chest Surgery. The C-reactive protein to albumin ratio is a prognostic factor for stage I non-small cell lung cancer in elderly patients: JACS1303. Surg Today. 2022 Oct;52(10):1463-1471.

50. Miyoshi S, Nishibuchi I, Murakami Y, Katsuta T, Imano N, Hirokawa J, Hamai Y, Emi M, Okada M, Nagata Y. Long-term results of chemoradiotherapy with elective nodal irradiation for resectable locally advanced esophageal cancer in three-dimensional planning system. Int J Clin Oncol. 2023 Jan 16. doi: 10.1007/s10147-023-02290-5. Epub 2023 Jan 16.

51.  Nakao M, Saji H, Mun M, Nakamura H, Okumura N, Tsuchida M, Sonobe M, Miyazaki T, Aokage K, Haruki T, Okada M, Suzuki K, Chida M. Prognostic Impact of Mediastinal Lymph Node Dissection in Octogenarians With Lung Cancer: JACS1303. Clin Lung Cancer. 2022 May;23(3):e176-e184. 

52. Nakao S, Yamaguchi K, Iwamoto H, Kagimoto A, Mimae T, Tsutani Y, Miyata Y, Hamada H, Okada M, Hattori N. Role of soluble receptor for advanced glycation end products in postoperative fibrotic lung injury. Ann Thorac Surg. 2022 May;113(5):1617-1623. 

53. Ohsawa M, Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, Hirohata R, Kitasaki N, Okada M.　Blood biomarkers as predictors of pathological lymph node metastasis in clinical stage T1N0 esophageal squamous cell carcinoma.　Dis Esophagus. 2022 Dec 31;36(1):doac042. doi: 10.1093/dote/doac042.

54. Okada M, Kato K, Cho BC, Takahashi M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Matsumura Y, Takazawa A, Kitagawa Y. Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3). Clin Cancer Res. 2022 Aug 2;28(15):3277-3286.

55. Okada M, Mimae T, Miyata Y. Segmentectomy and wedge resection should be distinguished as sublobar resections for lung cancer. Ann Thorac Surg. 2023 Mar 22:S0003-4975(23)00296-5. doi: 10.1016/j.athoracsur.2023.03.021. Online ahead of print.

56. Saito Y, Hamamoto Y, Hirata K, Yamasaki M, Watanabe M, Abe T, Tsubosa Y, Hamai Y, Murakami K, Bamba T, Yoshii T, Tsuda M, Watanabe M, Ueno M, Kitagawa Y. Real-world management and outcomes of older patients with locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study. BMC Cancer 23: 283, 2023.

57. Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, Aoki T, Okami J, Yoshino I, Ito H, Okumura N, Yamaguchi M, Ikeda N, Wakabayashi M, Nakamura K, Fukuda H, Nakamura S, Mitsudomi T, Watanabe SI, Asamura H; West Japan Oncology Group and Japan Clinical Oncology Group. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022 Apr 23;399(10335):1607-1617.

58. Shimada Y, Yoshioka Y, Kudo Y, Mimae T, Miyata Y, Adachi H, Ito H, Okada M, Ohira T, Matsubayashi J, Ochiya T, Ikeda N. Extracellular vesicle-associated microRNA signatures related to lymphovascular invasion in early-stage lung adenocarcinoma. Sci Rep. 2023 Mar 24;13(1):4823. doi: 10.1038/s41598-023-32041-5.

59. Shimomura A, Nagahashi M, Kumamaru H, Aogi K, Asaga S, Hayashi N, Iijima K, Kadoya T, Kojima Y, Kubo M, Miyashita M, Miyata H, Niikura N, Ogo E, Tamura K, Tanakura K, Yoshida M, Yamamoto Y, Imoto S, Jinno H: Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan. Breast Cancer 29: 985-992, 2022.(IF2.695)

60. Suzuki K, Sasada S, Kimura Y, Emi A, Kadoya T, Okada M. Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer. Anticancer Res. 2022 Dec;42(12):5945-5949.

61.  Suzuki K, Sasada S, Nishi H, Kimura Y, Shintani T, Emi A, Masumoto N, Kadoya T, Kawaguchi H, Okada M. Impact of oral hygiene on febrile neutropenia during breast cancer chemotherapy. Breast Cancer. 2023 Jan;30(1):151-155. doi: 10.1007/s12282-022-01410-9. Epub 2022 Oct 21.

62. Tada K, Kumamaru H, Miyata H, Asaga S, Iijima K, Ogo E, Kadoya T, Kubo M, Kojima Y, Tanakura K, Tamura K, Nagahashi M, Niikura N, Hayashi N, Miyashita M, Yoshida M, Ohno S, Imoto S, Jinno H: Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018. Breast Cancer. in press, 2022.(IF2.695)

63. Takamochi K, Suzuki K, Tsuboi M, Niho S, Ishikura S, Oyamada S, Yamaguchi T, Okada M; Advanced Clinical Trial Chest Surgery Group. Randomized phase II trial of pemetrexed-cisplatin plus bevacizumab or thoracic radiotherapy followed by surgery for stage IIIA (N2) nonsquamous non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 Sep;164(3):661-671.

64. Takamochi K, Tsuboi M, Okada M, Niho S, Ishikura S, Oyamada S, Yamaguchi T, Suzuki K; Advanced Clinical Trial Chest Surgery Group (ACTG).　S-1 + Cisplatin with Concurrent Radiotherapy Followed by Surgery for Stage IIIA (N2) Lung Squamous Cell Carcinoma: Results of a Phase II Trial.　　Ann Surg Oncol. 2022 Dec;29(13):8198-8206.

65. Terada M, Miyashita M, Kumamaru H, Miyata H, Tamura K, Yoshida M, Ogo E, Nagahashi M, Asaga S, Kojima Y, Kadoya T, Aogi K, Niikura N, Iijima K, Hayashi N, Kubo M, Yamamoto Y, Jinno H: Surgical treatment trends and identification of primary breast tumors after surgery in occult breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry. Breast Cancer 29: 698-708, 2022.(IF2.695)

66. Tokumo K, Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Okada M, Hamada H, Hattori N. Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition. Cancers (Basel). 2023 Feb 8;15(4):1092. doi: 10.3390/cancers15041092.

67. Tsubokawa N, Mimura T, Tadokoro K, Yamashita Y. Classification based on skeletal muscle mass and the severity of lung emphysema impacts on clinical outcomes after anatomical resection for lung cancer. Jpn J Clin Onol.2022 Aug 5; 52 (8):917-924, 2022.

68. Tsutani Y, Ito M, Shimada Y, Ito H, Ikeda N, Nakayama H, Okada M. The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma. J Thorac Cardiovasc Surg. 2022 Nov;164(5):1306-1315.e4.

69. Ueda D, Tsutani Y, Kamigaichi A, Kawamoto N, Tsubokawa N, Ito M, Mimae T, Miyata Y, Okada M. Impact of the Amount of Preoperative Erector Spinae Muscle in Stage I Non-Small Cell Lung Cancer. Eur J Cardiothorac Surg. 2022 Dec 2;63(1):ezac510. doi: 10.1093/ejcts/ezac510.

70. Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M: Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR. BMC med 20: 136, 2022.(IF8.775)

71.  Yamada A, Hayashi N, Kumamaru H, Nagahashi M, Usune S, Asaga S, Iijima K, Kadoya T, Kojima Y, Kubo M, Miyashita M, Miyata H, Ogo E, Tamura K, Tanakura K, Tada K, Niikura N, Yoshida M, Ohno S, Ishikawa T, Narui K, Endo I, Imoto S, Jinno H: Prognostic impact of postoperative radiotherapy in patients with breast cancer and with pT1-2 and 1-3 lymph node metastases: A retrospective cohort study based on the Japanese Breast Cancer Registry. Eur J Cancer 172: 31-40, 2022.(IF10.002)

72. Yamaguchi A, Ishitobi M, Nagura N, Shimo A, Seki H, Ogiya A, Sakurai T, Seto Y, Oshiro C, Sasada S, Kato M, Kawate T, Kondo N, Narui K, Nakagawa T, Nogi H, Yamauchi C, Tsugawa K, Kajiura Y, Shien T. Classification of Local Recurrence After Nipple-Sparing Mastectomy Based on Location: The Features of Nipple-Areolar Recurrence Differ from Those of Other Local Recurrences. Ann Surg Oncol 30: 1678-1686, 2023.

73. Yamakado R, Ishitobi M, Kondo N, Yamauchi C, Sasada S, Nogi H, Saiga M, Ogiya A, Narui K, Seki H, Nagura N, Shimo A, Sakurai T, Niikura N, Mori H, Shien T; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Physicians' perception about the impact of breast reconstruction on patient prognosis: a survey in Japan. Breast Cancer 30: 302-308, 2023.

74. Yoshikawa Y, Imamura M, Yamauchi M, Hayes CN, Aikata H, Okamoto W, Miyata Y, Okada M, Hattori N, Sugiyama K, Yoshioka Y, Toratani S, Takechi M, Ichinohe T, Ueda T, Takeno S, Kobayashi T, Ohdan H, Teishima J, Hide M, Nagata Y, Kudo Y, Iida K, Chayama K. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors. BMC Cancer. 2022 Nov 29;22(1):1232.

75. 川又あゆみ，惠美純子，藤本睦，甲斐あずさ，鈴木江梨，小林美恵，笹田伸介，舛本法生，角舎学行，岡田守人．腎細胞癌の根治的腎摘除術後に乳房内転移を来した 1 例．癌と化学療法 49: 1891-1892，2022.

76. 見前隆洋，岡田守人：末梢小型非小細胞肺癌に対する根治的区域切除の幕開け．胸部外科76：4-8，2023．